In summary, treatment with IgM‐IVIg in experimental stroke prevented the MCAO‐induced reduction in plasma B cells abundances and circulating IgM and IgA antibody concentrations, reductions in transitional B cells and had no effect on other antibody‐secreting cellular subsets (B1 and MZ B cells). The gene discussed is CD79A; the disease is Stroke.